Sandy Trieu

All Publications

• Perceptions, Uses, and Information Sources of Medical Cannabis Among Patients With Cancer ADVANCES IN RADIATION ONCOLOGY Qu, V., Hui, C., Hall, J., Taparra, K., Kollipara, T., Trieu, S., Beadle, B., Soltys, S., Pollom, E. L. 2025; 10 (3)

  View details for DOI 10.1016/j.adro.2024.101678

  View details for Web of Science ID 001409975300001

• Perceptions, Uses, and Information Sources of Medical Cannabis Among Patients With Cancer. Advances in radiation oncology Qu, V., Hui, C., Hall, J., Taparra, K., Kollipara, T., Trieu, S., Beadle, B., Soltys, S., Pollom, E. L. 2025; 10 (3): 101678

  Abstract

  Although medical cannabis (MC) has been shown to relieve cancer- and treatment-related symptoms, there is increasing misinformation regarding its antitumor efficacy. We aimed to identify opportunities for oncologists to communicate evidence-based guidance to patients regarding its use.Patients with cancer seen in radiation oncology clinic between June 2022 and July 2023 were surveyed with a questionnaire regarding their perceptions and information sources of MC. Associations between survey responses and demographic and disease variables were evaluated. Qualitative thematic analysis was performed on narrative responses in search of common themes.Eighty-four patients (84% completion rate) were included in the analysis. Most (83.3%) strongly agreed or agreed that MC can provide symptom relief, whereas a subset of patients (15.5%) strongly agreed or agreed that MC can cure cancer. This latter subcohort was significantly more likely to identify as Hispanic/Latino (38.5% vs 9.9%, P = .009) and less likely to be up to date on COVID-19 vaccinations (30.8% vs 8.5%, P = 0.044). Identifying as Hispanic/Latino remained significantly associated with strongly agreeing or agreeing that MC can cure cancer on bivariate analysis (odds ratio, 6.528; 95% CI, 1.477-28.715; P = .012). Education level, other sociodemographic characteristics, and sources for information about MC were not significantly different between these patients. Thematic analysis revealed that patients hoped to learn more about MC from their oncologists but perceived them to be unknowledgeable on the subject.Although most patients consider MC to be a valuable addition to conventional therapies for managing refractory symptoms, a subset believed it had potential as an anticancer therapy. Many patients rely on unregulated sources, highlighting the need for providers to address misinformation, bridge knowledge gaps, and clarify its use.

  View details for DOI 10.1016/j.adro.2024.101678

  View details for PubMedID 40546850

  View details for PubMedCentralID PMC12181627

• Dronabinol for the Treatment of Paraneoplastic Night Sweats in Cancer Patients: A Report of Five Cases JOURNAL OF PALLIATIVE MEDICINE Carr, C., Vertelney, H., Fronk, J., Trieu, S. 2019; 22 (10): 1221–23

  View details for DOI 10.1089/jpm.2018.0551

  View details for Web of Science ID 000496264500011

• PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., Harman, S., Dwyer, P., Bosch, J., Shaw, H., Safari, S., Oden, R., Morrison, T., Blayney, D. LIPPINCOTT WILLIAMS & WILKINS. 2013: S1324

  View details for Web of Science ID 000339624906208

• Outpatient palliative care at a tertiary cancer center: Perceptions, pathways, and pitfalls Ramchandran, K., Trieu, S., Harman, S., Passaglia, J., Rodriguez, J., Dwyer, P., Oden, R. AMER SOC CLINICAL ONCOLOGY. 2012

  View details for DOI 10.1200/jco.2012.30.34_suppl.28

  View details for Web of Science ID 000208943900029

• Malignancy in the Setting of the Anti-Synthetase Syndrome JCR-JOURNAL OF CLINICAL RHEUMATOLOGY Rozelle, A., Trieu, S., Chung, L. 2008; 14 (5): 285-288

  Abstract

  Malignancy and interstitial lung disease (ILD) are 2 conditions associated with dermatomyositis (DM) that are responsible for a significant portion of the morbidity and mortality related to this disease; however, they rarely occur in the same patient. The antisynthetase syndrome consists of several characteristics, including ILD, arthritis, Raynaud phenomenon, "mechanic's hands," and positive antibodies to tRNA synthetases, which have each been negatively associated with cancer. When patients with DM present with such characteristics, clinicians may be falsely reassured that a thorough malignancy screen is unnecessary. We describe a patient who presented with the antisynthetase syndrome and was subsequently found to have colon cancer. Removal of the cancer led to resolution of the myositis and lung disease, but the patient's rash and arthritis persisted and ultimately required immunosuppressive therapy. We provide a review of the literature describing the concurrence of both this syndrome and ILD alone, with malignancy. We conclude that a thorough and expedited age-appropriate malignancy work up is indicated in all patients with a new diagnosis of DM, despite the presence of disease characteristics that are usually not associated with cancer.

  View details for DOI 10.1097/RHU.0b013e31817d116f

  View details for Web of Science ID 000260154000008

  View details for PubMedID 18664993